Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.56 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.51 |
| ▸ | F13A1 | P00488 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051517 | 0.97 | GHSR (0.53) | GHSRDPP3F13A1TGM2CYP2C19 | |
| SCHEMBL2193319 | 0.90 | GHSR (0.52) | GHSRDPP3F13A1TGM2CAPN1 | |
| SCHEMBL18933365 | 0.88 | DPP3 (0.53) | GHSRDPP3F13A1TGM2OPRM1 | |
| SCHEMBL14906478 | 0.88 | DPP3 (0.49) | GHSRDPP3OPRM1BCHE | |
| SCHEMBL14906600 | 0.88 | DPP3 (0.49) | GHSRDPP3OPRM1BCHE | |
| SCHEMBL23380930 | 0.87 | GHSR (0.57) | GHSRDPP3OPRM1 | |
| SCHEMBL29812309 | 0.87 | DPP3 (0.64) | GHSRDPP3OPRM1 | |
| SCHEMBL14903326 | 0.86 | DPP3 (0.49) | GHSRDPP3OPRM1 | |
| SCHEMBL30668967 | 0.85 | DPP3 (0.55) | GHSRDPP3CAPN1CTSB | |
| SCHEMBL29533411 | 0.85 | GHSR (0.65) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689082-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9 | Scribe Therapeutics Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-119019505-B | PROTAC polypeptide of targeted ZMYND protein and application thereof | 西安交通大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-117843641-B | NSD3 inhibitor and preparation method and application thereof | 和径医药科技（上海）有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025082409-A1 | PURINE COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025076000-A2 | COMPOSITIONS AND METHODS FOR MODULATING CHROMATIN STATE | THE UNIVERSITY OF CHICAGO (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250099405-A1 | COMPOSITIONS, METHODS, AND DEVELOPMENT OF ARID4B INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2024260445-A1 | THIAZOLIDINEDIONE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海科技大学 | 2024-12-26 | — | — | WO | disclosed |
| CN-119174759-A | Thiazolidinedione compound, pharmaceutical composition and application thereof | 上海科技大学 | 2024-12-24 | — | — | CN | disclosed |
| EP-4465977-A2 | COMPOSITIONS, METHODS, AND DEVELOPMENT OF ARID4B INHIBITORS | University Of Kentucky Research Foundation (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-119019505-A | PROTAC polypeptide of targeted ZMYND protein and application thereof | 西安交通大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024238906-A2 | EPIGENETIC REPRESSION PROTEIN THERAPY FOR RASOPATHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024206555-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9 | SCRIBE THERAPEUTICS INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-117843641-A | NSD3 inhibitor and preparation method and application thereof | 和径医药科技（上海）有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023141467-A2 | COMPOSITIONS, METHODS, AND DEVELOPMENT OF ARID4B INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099405-A1 | COMPOSITIONS, METHODS, AND DEVELOPMENT OF ARID4B INHIBITORS | ARID2, ACIN1, ATAD2B | GHSR 3981/4885DPP3 3782/4885F13A1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.